A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Inclusion Criteria: All participants * The informed consent must be signed before any study specific tests or procedures are done; * Male and female white participants; * Women of childbearing potential can only be included in the study if a pregnancy test is negative. Women of childbearing potential must agree to use adequate contraception when sexually active. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). This applies from signing the informed consent form until follow up visit. * Body mass index (BMI): 18 to 34 kg/m2 (both inclusive); * Age: 18 to 79 years (both inclusive) at the screening visit; * Men must agree to use adequate contraception when being sexually active. This applies from signing of the informed consent until 12 weeks after the last study drug administration. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices); * Ability to understand and follow study-related instructions. Participants with hepatic impairment * Participants with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, u…